Both Ozempic and Mounjaro are once-weekly injectable medications primarily approved for managing Type 2 Diabetes. Both help lower blood sugar, reduce A1C levels, and offer the secondary benefit of weight loss. But they work through different mechanisms, come with different dosing schedules, and have important differences in cost and cardiovascular data that might matter for your situation.
This guide compares the two so you can have a more informed conversation with your doctor about which might be the better fit for your diabetes management.
Ozempic contains semaglutide, which works by mimicking a single gut hormone called GLP-1. This hormone signals your pancreas to release insulin when your blood sugar is high, suppresses glucagon (which raises blood sugar), and slows stomach emptying so you feel full longer.
Mounjaro contains tirzepatide, which mimics two gut hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The dual-hormone approach provides stronger insulin signaling and may work through additional pathways that semaglutide doesn't, particularly in how the body processes glucose.
In practical terms, both medications address Type 2 Diabetes by helping your body use insulin more effectively and control blood sugar levels. The single-hormone approach of Ozempic is well-proven. The dual-hormone approach of Mounjaro appears to offer additional benefit for some patients, particularly for A1C reduction.
Clinical trials comparing the two medications at maximum therapeutic doses show measurable differences in A1C reduction:
| Outcome | Ozempic | Mounjaro |
|---|---|---|
| Typical A1C reduction | 1.5% to 1.8% reduction | 2.0% to 2.4% reduction |
| Patients reaching A1C <7% | Approximately 60-70% | Approximately 70-85% |
| Average weight loss (secondary effect) | 5 to 8 pounds on average | 8 to 12 pounds on average |
The data suggests Mounjaro provides stronger A1C reduction on average. However, individual results vary considerably. Some patients respond extremely well to Ozempic while others show a better response to Mounjaro. Your doctor will likely recommend starting with one, measuring your A1C response after 3 months, and adjusting if needed.
Both start at a low dose and increase gradually to minimize side effects. The titration protocols differ:
| Phase | Ozempic | Mounjaro |
|---|---|---|
| Starting dose | 0.25 mg weekly | 2.5 mg weekly |
| Dose increases | 0.25 mg → 0.5 mg → 1 mg → 2 mg | 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg |
| Interval between increases | 4 weeks | 4 weeks |
| Time to maximum dose | 12 weeks (3 months) | 20 weeks (5 months) |
| Typical maintenance dose | 1 mg or 2 mg weekly | 5 mg to 15 mg weekly |
Ozempic reaches full therapeutic dosing faster. Mounjaro takes longer to titrate but offers more granular dosing steps. Some doctors keep patients on the lowest effective dose rather than maxing out, so Mounjaro's additional dose options provide more flexibility.
Both medications work on similar metabolic pathways, so their side effect profiles are largely comparable. The most common side effects include nausea, vomiting, diarrhea, constipation, and stomach discomfort. These are typically most pronounced during the first 1 to 2 weeks after each dose increase and usually improve as your body adjusts.
Clinical trial data shows roughly similar side effect rates between the two. Some individual patients tolerate one better than the other, but there's no reliable way to predict your personal experience in advance. If side effects are unmanageable with one medication, switching to the other is a reasonable option to discuss with your doctor.
Both medications carry a black-box warning about pancreatitis (though this is very rare) and should not be used if you have a personal or family history of medullary thyroid cancer.
This is an area where the medications differ meaningfully in terms of available evidence:
Ozempic has established cardiovascular outcome data from major trials (SUSTAIN-6 and SELECT trials), showing that semaglutide reduces the risk of heart attack, stroke, and cardiovascular death in people with Type 2 Diabetes, especially those with existing heart disease or high cardiovascular risk.
Mounjaro's cardiovascular outcomes trial is still ongoing, so long-term cardiovascular benefit data is not yet available. This doesn't mean it lacks cardiovascular benefit, only that we don't yet have published trial data demonstrating it. This may matter if you have a history of heart disease or significant cardiovascular risk factors, as your doctor may have more confidence recommending Ozempic based on current evidence.
| Scenario | Ozempic | Mounjaro |
|---|---|---|
| List price | ~$968/mo | ~$1,080/mo |
| Manufacturer savings card (with commercial insurance) | As low as $25/mo | As low as $25/mo |
| Direct-pay program (no insurance) | $349/mo via NovoCare | No direct-pay program available |
| Medicare (starting July 2026) | $50/mo via GLP-1 Bridge | $50/mo via GLP-1 Bridge |
For those with commercial insurance, both medications can be extremely affordable with manufacturer savings cards, often dropping to $25 per month or less. Medicare beneficiaries will have access to both through the new GLP-1 Bridge program starting July 2026 at $50 per month.
The meaningful cost difference emerges for uninsured patients. Ozempic offers a direct-pay option through NovoCare at $349 per month, making it accessible for those without insurance. Mounjaro does not currently offer a direct-pay program for uninsured patients, which can make it prohibitively expensive at the full list price.
For current pricing and insurance coverage details tailored to your specific plan, our Cost Estimator tool can provide more accurate information.
Both medications are FDA-approved for Type 2 Diabetes, so most health insurance plans cover them. However, formularies, prior authorization requirements, and coverage restrictions vary by plan. Some plans may prefer one over the other based on their negotiated pricing.
Ask your doctor or insurance company specifically whether Ozempic and Mounjaro are covered and at what tier, as this may be the deciding factor for many people.
There's no universally best option, but here are practical considerations:
Choose Ozempic if you have significant cardiovascular disease or risk, want to reach maximum therapeutic dosing faster, prefer medications with the longest track record of cardiovascular benefit, or need an affordable direct-pay option without insurance.
Choose Mounjaro if maximizing A1C reduction is your primary goal, you prefer more flexibility in maintenance dosing, you have commercial insurance that covers it at the same cost as Ozempic, or you've tried semaglutide and the A1C reduction wasn't adequate.
For many people, insurance coverage and cost will be the deciding factors. Both medications are effective and have proven safety profiles. Starting with one and measuring your A1C response after 3 months is a standard approach. If you're not reaching your target A1C, switching to the other medication is a reasonable next step.
Use our free calculator to manage your GLP-1 dosing timeline and estimate your costs.
Open the GLP-1 Calculator